Проблемы низкой активности и ремиссии при системной красной волчанке
https://doi.org/10.14412/1995-4484-2019-218-221
Аннотация
За последние годы увеличилась долгосрочная выживаемость пациентов с системной красной волчанкой (СКВ) более чем до 90%, но все еще остается достаточно много нерешенных проблем. Хотя главной целью концепции «Лечение СКВ до достижения цели» является «ремиссия симптомов и отсутствие поражения органов», было признано, что общепринятого определения ремиссии при СКВ в настоящее время не существует. В статье обсуждаются различные варианты определения понятия «ремиссия» при СКВ.
Об авторах
С. К. СоловьевРоссия
115522, Москва, Каширское шоссе, 34А
Е. А. Асеева
Россия
115522, Москва, Каширское шоссе, 34А
Е. Г. Зоткин
Россия
115522, Москва, Каширское шоссе, 34А
С. Ю. Шкиреева
Россия
115522, Москва, Каширское шоссе, 34А
Е. Л. Насонов
Россия
115522, Москва, Каширское шоссе, 34А;
119991, Москва, ул. Трубецкая, 8, стр. 2
Список литературы
1. Houssiau FA, Vasconcelos C, D’Cruz D, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing lowdose and high-dose intravenous cyclophosphamide. Ann Rheum Dis. 2010;69:61-4. doi: 10.1136/ard.2008.102533
2. Bexelius C, Wachtmeister K, Skare P,et al. Drivers of cost and health-related quality of life in patients with systemic lupus erythematosus (SLE): a Swedish nationwide study based on patient reports. Lupus. 2013;22:793-801. doi: 10.1177/0961203313491849
3. Eder L, Urowitz MB, Gladman DD. Damage in lupus patients – what have we learned so far? Lupus. 2013 Oct;22(12):1225-31.
4. Rahman P, Gladman DD, Urowitz MB, et al. Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. Lupus. 2001;10(2):93-6. doi: 10.1191/096120301670679959
5. Wilhelm TR, Magder LS, Petri M. Remission in systemic lupus erythematosus: durable remission is rare. Ann Rheum Dis. 2017 Mar;76(3):547-53. doi: 10.1136/annrheumdis-2016-209489
6. Dubois EL. Lupus Erythematosus. 2 nd ed. Los Angeles: University of Southern California Press; 1976. 243 p.
7. Van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014;73:958-67. doi: 10.1136/annrheumdis-2013-205139
8. Steiman AJ, Urowitz MB, Ibanez D, et al. Prolonged clinical remission in patients with systemic lupus erythematosus. J Rheumatol. 2014;41:1808-16. doi: 10.3899/jrheum.131137
9. Van Vollenhoven R, Voskuyl A, Bertsias G, et al. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Ann Rheum Dis. 2017 Mar;76(3):554-61. doi: 10.1136/annrheumdis-2016-209519. Epub 2016 Nov 24.
10. Franklyn K, Lau CS, Navarra SV, et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis. 2016 Sep;75(9):1615-21. doi: 10.1136/annrheumdis-2015-207726
11. Heller CA, Schur PH. Serological and clinical remission in systemic lupus erythematosus. J Rheumatol. 1985 Oct;12(5):916-8.
12. Drenkard C, Villa AR, Garcia-Padilla C, et al. Remission of systematic lupus erythematosus. Medicine (Baltimore). 1996;75:88-98. doi: 10.1097/00005792-199603000-00005
13. Urowitz MB, Feletar M, Bruce IN, et al. Prolonged remission in systemic lupus erythematosus. J Rheumatol. 2005 Aug;32(8):1467-72.
14. Medina-Quinones CV, Ramos-Merino L, Ruiz-Sada P, Isenberg D. Analysis of complete remission in systemic lupus erythematosus patients over a 32-year period. Arthritis Care Res (Hoboken). 2016 Jul;68(7):981-7. doi: 10.1002/acr.22774
15. Zen M, Iaccarino L, Gatto M, et al. Prolonged remission in Caucasian patients with SLE: prevalence and outcomes. Ann Rheum Dis. 2015;74:2117-22. doi: 10.1136/annrheumdis-2015-207347
16. Tselios K, Gladman DD, Touma Z, et al. Clinical remission and low disease activity have comparable outcomes over 10 years in systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2018 Jul 28. doi: 10.1002/acr.23720
17. Aljohani R, Gladman DD, Su J, Urowitz MB. Comparison of systemic lupus erythematosus (SLE) patients managed early after diagnosis in specialty versus community care clinics. Clin Rheumatol. 2017 Aug;36(8):1773-8. doi: 10.1007/s10067-017-3713-7
18. Mok CC, Wong RW, Lau CS. Lupus nephritis in Southern Chinese patients: clinic-pathologic findings and long-term outcome. Am J Kidney Dis. 1999;34:315-23. doi: 10.1016/S0272-6386(99)70361-6
19. Illei GG, Takada K, Parkin D, et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term follow-up of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum. 2002;46:995-1002. doi: 10.1002/art.10142
20. Lee BS, Cho HY, Kim EJ, et al. Clinical outcomes of childhood lupus nephritis: a single center’s experience. Pediatr Nephrol. 2007;22:222-31. doi: 10.1007/s00467-006-0286-0
21. So MW, Koo BS, Kim YG, et al. Predictive value of remission status after 6 months induction therapy in patients with proliferative lupus nephritis: a retrospective analysis. Clin Rheumatol. 2011;30:1399-405.
22. Fernandes das Neves M, Irlapati RV, Isenberg D. Assessment of long-term remission in lupus nephritis patients: a retrospective analysis over 30 years. Rheumatology (Oxford). 2015;54:1403-7. doi: 10.1093/rheumatology/kev003
23. Carter EE, Barr SG, Clarke AE. The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol. 2016 Oct;12(10):605-20.
24. Ruiz-Irastorza G, Danza A, Khamashta M. Glucocorticoid use and abuse in SLE. Rheumatology (Oxford). 2012 Jul;51(7):1145-53. doi: 10.1093/rheumatology/ker410
25. Iaccarino L, Andreoli L, Bartoloni Bocci L, et al. Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study. J Autoimmun. 2018;86:1-8. doi: 10.1016/j.jaut.2017.09.004
26. Kraaij T, Kamerling WA, de Rooij NM, et al. The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus. J Autoimmun. 2018;91:45-54. doi: 10.1016/j.jaut.2018.03.003
27. Bruce IN, Urowitz M, van Vollenhoven R, et al. Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care. Lupus. 2016 Jun;25(7):699-709.
28. Doria A, Bass D, Schwarting A, et al. A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus. Lupus. 2018 Aug;27(9):1489-98. doi: 10.1177/0961203318777634
29. Beckwith H, Lightstone L. Rituximab in systemic lupus erythematosus and lupus nephritis. Nephron Clin Pract.2014;128(3-4):250-4. doi: 10.1159/000368585
30. Alshaiki F, Obaid E, Almuallim A, et al. Outcomes of rituximab therapy in refractory lupus: A meta-analysis. Eur J Rheumatol. 2018 Jul;5(2):118-26. doi: 10.5152/eurjrheum.2018.17096
31. Gracia-Tello B, Ezeonyeji A, Isenberg D. The use of rituximab in newly diagnosed patients with systemic lupus erythematosus: longterm steroid saving capacity and clinical effectiveness. Lupus Sci Med. 2017;4:e000182. doi: 10.1136/lupus-2016-000182
32. Меснянкина АА, Соловьев СК, Асеева ЕА, Насонов ЕЛ. Эффективность генно-инженерной биологической терапии и особенности гуморального иммунитета у больных системной красной волчанкой. Научно-практическая ревматология. 2018;56(3):302-9. doi: 10.14412/1995-4484-2018-302-309
Рецензия
Для цитирования:
Соловьев С.К., Асеева Е.А., Зоткин Е.Г., Шкиреева С.Ю., Насонов Е.Л. Проблемы низкой активности и ремиссии при системной красной волчанке. Научно-практическая ревматология. 2019;57(2):218-221. https://doi.org/10.14412/1995-4484-2019-218-221
For citation:
Soloviev S.K., Aseeva E.A., Zotkin E.G., Kireeva S.Yu., Nasonov E.L. Problems of low activity and remission in systemic lupus erythematosus. Rheumatology Science and Practice. 2019;57(2):218-221. (In Russ.) https://doi.org/10.14412/1995-4484-2019-218-221